Cocrystal Pharma (NASDAQ:COCP) is a dynamic biotechnology firm focused on discovering, developing, and commercializing novel antiviral therapeutics. The company employs unique proprietary technologies to create first-in-class and best-in-class antiviral drugs aimed at treating diseases caused by the most serious and widespread viruses, including influenza, coronavirus, and hepatitis C. Cocrystal Pharma's mission revolves around leveraging its innovative drug discovery platform to generate effective treatments that can address unmet medical needs in the fight against viral infections. Through strategic collaborations and internal research programs, it actively pursues the development of new antiviral compounds, striving to lead advancements in the field of antiviral drug development. With a commitment to innovation and improving patient care, Cocrystal Pharma is dedicated to achieving new milestones in antiviral therapy.